{"id":"W4399394190","doi":"10.1200/jco.2024.42.16_suppl.4508","title":"Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Medicine; Axitinib; Renal cell carcinoma; Sunitinib; Javelin; Internal medicine; Oncology; Avelumab; Urology; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002646717,0.0006920696,0.001244879,0.0003498663,0.0002561593,0.0007833223,0.0005228215,0.0006503016,0.003122285],"category_scores_gemma":[0.001267776,0.000301796,0.00208067,0.0005117311,0.0004321705,0.0005528753,0.0003777303,0.0017048,0.0004522598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000937562,"about_ca_system_score_gemma":0.0008128107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008272664,"about_ca_topic_score_gemma":0.002741591,"domain_scores_codex":[0.9993638,0.0003563004,0.00005102741,0.00009892441,0.00005710484,0.00007292155],"domain_scores_gemma":[0.9992241,0.0001978843,0.0002615253,0.00005640841,0.00003480814,0.0002252881],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9215494,0.00481574,0.01476704,0.0009211331,0.003558545,0.00009276191,0.0001051858,0.0019333,0.004396434,0.0001241839,0.002775354,0.04496088],"study_design_scores_gemma":[0.6228523,0.2723689,0.08483908,0.0001246135,0.006572243,0.0006139403,0.0001032329,0.003377988,0.003099621,0.0006067888,0.005391593,0.00004965147],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989431,0.004820092,0.0004038608,0.0003011176,0.00008523685,0.0008591861,0.002268634,0.00005695647,0.001773794],"genre_scores_gemma":[0.993885,0.001235359,0.0006304143,0.0002626351,0.00009446723,0.0006442216,0.00215468,0.00001371573,0.001079459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003122285,"threshold_uncertainty_score":0.01399732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1058451667425589,"score_gpt":0.413403558211702,"score_spread":0.3075583914691432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}